We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Point-of-Care Immunoassay Analyzer on Display at AACC Annual Meeting

By LabMedica International staff writers
Posted on 02 Aug 2016
Image: The LABGEO IB10 chemistry analyzer (Photo courtesy of Samsung / Thermo Fisher Scientific).
Image: The LABGEO IB10 chemistry analyzer (Photo courtesy of Samsung / Thermo Fisher Scientific).
A small, simple to use basic immunoassay analyzer designed for point-of-care (POC) settings is available for inspection in the Thermo Fisher Scientific (Fremont, CA, USA) Booth 2145 at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

The Samsung LABGEO IB10 chemistry analyzer is the result of the partnership between Samsung (Suwon, South Korea) and Thermo Fisher Scientific.

The LABGEO IB10 is a small, simple to use basic immunoassay analyzer designed for POC settings. It was designed to measure TnI, D-Dimer, NT-proBNP, Myoglobulin, CK-MB, TSH, HCG, and PCT (Procalcitonin) within 20 minutes from a single use cartridge. Each cartridge includes calibration data, lot number, analyte listing, and expiration data.

The broad menu, short turn around time, and simplicity of the LABGEOIB10 make it ideal for satellite laboratories, physician offices, remote locations, and other settings where speed and convenience can improve productivity and patient compliance to treatment goals.

Related Links:
Thermo Fisher Scientific
AACC Annual Meeting & Clinical Lab Expo
Samsung
Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
INTEGRA BIOSCIENCES AG